Edwards Lifesciences’ (EW) Buy Rating Reiterated at BTIG Research

BTIG Research restated their buy rating on shares of Edwards Lifesciences (NYSE:EW) in a report issued on Tuesday,Benzinga reports. The firm currently has a $100.00 price target on the medical research company’s stock.

Several other research analysts also recently weighed in on EW. Canaccord Genuity Group restated a “hold” rating and set a $84.00 price target (up previously from $81.00) on shares of Edwards Lifesciences in a research report on Monday, November 3rd. Royal Bank Of Canada boosted their price objective on Edwards Lifesciences from $89.00 to $95.00 and gave the stock an “outperform” rating in a research note on Friday, October 31st. Piper Sandler restated an “overweight” rating and issued a $95.00 target price (up previously from $90.00) on shares of Edwards Lifesciences in a research report on Friday, October 31st. National Bankshares set a $92.00 price target on Edwards Lifesciences in a research note on Friday, October 31st. Finally, The Goldman Sachs Group set a $104.00 price target on Edwards Lifesciences and gave the stock a “buy” rating in a research report on Friday, October 31st. Three research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $91.39.

Edwards Lifesciences Stock Down 0.0%

Edwards Lifesciences stock opened at $86.78 on Tuesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. The stock has a market capitalization of $50.36 billion, a PE ratio of 12.49, a price-to-earnings-growth ratio of 3.97 and a beta of 1.03. The business has a 50 day simple moving average of $79.68 and a 200-day simple moving average of $78.37. Edwards Lifesciences has a 12 month low of $65.94 and a 12 month high of $87.40.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.59 by $0.08. The firm had revenue of $1.55 billion for the quarter, compared to analysts’ expectations of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The firm’s revenue for the quarter was up 14.7% compared to the same quarter last year. During the same quarter last year, the company earned $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. On average, analysts anticipate that Edwards Lifesciences will post 2.45 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Scott B. Ullem sold 13,000 shares of the business’s stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $83.08, for a total transaction of $1,080,040.00. Following the transaction, the chief financial officer owned 39,898 shares of the company’s stock, valued at approximately $3,314,725.84. The trade was a 24.58% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Daniel J. Lippis sold 1,020 shares of the firm’s stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $82.55, for a total transaction of $84,201.00. Following the sale, the vice president owned 22,002 shares of the company’s stock, valued at approximately $1,816,265.10. The trade was a 4.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 1.29% of the company’s stock.

Institutional Trading of Edwards Lifesciences

Hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. raised its position in shares of Edwards Lifesciences by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 70,363,210 shares of the medical research company’s stock valued at $5,472,147,000 after buying an additional 365,581 shares during the period. Wellington Management Group LLP increased its stake in Edwards Lifesciences by 4.9% during the third quarter. Wellington Management Group LLP now owns 20,804,416 shares of the medical research company’s stock worth $1,617,959,000 after acquiring an additional 977,933 shares during the last quarter. Bank of New York Mellon Corp raised its position in Edwards Lifesciences by 8.1% in the third quarter. Bank of New York Mellon Corp now owns 19,010,227 shares of the medical research company’s stock valued at $1,478,425,000 after purchasing an additional 1,423,365 shares during the period. Jennison Associates LLC lifted its stake in shares of Edwards Lifesciences by 19.6% in the 3rd quarter. Jennison Associates LLC now owns 13,958,774 shares of the medical research company’s stock valued at $1,085,574,000 after purchasing an additional 2,287,783 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Edwards Lifesciences by 0.4% in the 2nd quarter. Geode Capital Management LLC now owns 12,722,416 shares of the medical research company’s stock valued at $990,074,000 after purchasing an additional 45,555 shares during the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.